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Abstract
Background: Loss-of-function CECR1 mutations cause polyarteritis nodosa (PAN) with childhood onset, an
autoinflammatory disorder without significant signs of autoimmunity. Herein we describe the unusual presentation
of an autoimmune phenotype with constitutive type I interferon activation in siblings with adenosine deaminase 2
(ADA2) deficiency.
Case presentation: We describe two siblings with early-onset recurrent strokes, arthritis, oral ulcers, discoid rash,
peripheral vascular occlusive disease and high antinuclear antibody titers. Assessment of interferon signatures in
blood revealed constitutive type I interferon activation. Aicardi-Goutières syndrome (AGS) was suspected, but no
mutation in the known AGS genes were detected. Whole exome sequencing identified compound heterozygosity
for a known and a novel mutation in the CECR1 gene. Functional consequences of the mutations were
demonstrated by marked reduction in ADA2 catalytic activity.
Conclusions: Our findings demonstrate that ADA2 deficiency can cause an unusual autoimmune phenotype
extending the phenotypic spectrum of PAN. Constitutive interferon I activation in patient blood suggests a possible
role of type I interferon in disease pathogenesis which may have therapeutic implications.
Keywords: Adenosine deaminase 2, CECR1, Systemic lupus erythematosus, Hypergammaglobulinaemia, Antinuclear
antibodies, Interferon signature
Background
Deficiency of adenosine deaminase 2 (ADA2) is a rare
systemic vascular inflammatory disorder, also known as
polyarteritis nodosa with childhood-onset (PAN; OMIM
615688). PAN is caused by autosomal recessive loss-of-
function mutations in the CECR1 gene encoding adeno-
sine deaminase 2 [1, 2]. Since the first description of
familial PAN in 2014, 19 pathogenic mutations have
been described. The disorder shows a variable age of
onset, although most patients present with symptoms in
the first decade [3, 4]. The main clinical findings include
early-onset recurrent strokes, livedo reticularis and
recurrent fever. Organ involvement, course and severity
vary largely, even among affected individuals of the same
family, ranging from mild skin disease to devastating
systemic disease. Whereas cytopenia and hypogammaglo-
bulinemia associated with varying degrees of
immunodeficiency have commonly been described in
ADA2-deficient patients [1, 4–7], signs of autoimmunity
have only rarely been recognized. Although the pathogen-
esis of the disease is currently not entirely understood,
markers of cellular immunity and macrophage activation
have shown to be increased, suggesting a role of ADA2 in
immune responses. Here we describe two siblings who
presented with early-onset cerebrovascular disease and
autoimmune features caused by ADA2 deficiency.
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Case presentation
Patient 1 was born after an uneventful pregnancy and
delivery to healthy nonconsanguineous Caucasian par-
ents. At 22 months of age, he presented with recurrent
episodes of unexplained fever, mouth ulcers and abdom-
inal pain with intermittently elevated C-reactive protein
(CRP). At age 3 years, he developed supranuclear oph-
thalmoplegia and right oculomotor nerve palsy. Cerebral
magnetic resonance imaging (MRI) and cerebrospinal
fluid (CSF) were unremarkable then. CRP and ESR were
markedly increased, as were serum IL-6 and s-IL2R.
Within 2 weeks, neurological symptoms resolved com-
pletely, but febrile episodes, abdominal pain and mouth
ulcers recurred. In addition, he developed livedo reticu-
laris and arthralgia (Fig. 1a). Follow-up blood tests re-
vealed chronic inflammation. Antinuclear antibodies
(ANA) were positive (1:320) with a homogenous pattern,
while antibodies to extractable nuclear antigens (ENA),
anti-double-stranded DNA (dsDNA)-, anticardiolipin
(aCL)- and anti-beta2-glycoprotein (anti-ß2GP)-anti-
bodies were negative, as were anti-neutrophilic anti-
bodies (ANCA). At age 5 years, he presented with mild
right-sided hemiparesis. Cerebral MRI revealed a 5 mm
signal alteration in the brainstem consistent with ische-
mia. MR angiography was without pathologic findings.
An underlying coagulopathy and infections were ex-
cluded. ANA titer was increased to 1:640. Therapy with
heparin was started, followed by low-dose acetylsalicylic
acid (ASA). Complete neurological remission was
achieved within 1 week. From age 7 to 9 years, the pa-
tient experienced recurrent attacks of vertigo and head-
aches, episodes of abdominal pain and recurrent mouth
ulcers. He continued to have prominent livedo and arth-
ralgia of small joints and knees accompanied by swelling
and morning stiffness. At 10 years of age, he suffered an
episode of severe ataxia, nystagmus, and diplopia.
Laboratory findings included increased markers of in-
flammation, hypergammaglobulinemia and an ANA titer
of 1:1280. Lupus-anticoagulant was transiently positive,
while complement factors C3 and C4 were repeatedly
within normal limits. A skin biopsy revealed unspecific
teleangiectasia of small vessels with sparse inflammatory
infiltrates. At the last follow-up visit ANA titer was
1:1280 and anti-nucleosome antibodies were positive for
the first time.
Patient 2 is the younger brother of patient 1. He
presented at 2.5 years of age with acute right-sided hemi-
paresis, accompanied by annular violaceous skin lesions
on both calves and mouth ulcers. Cerebral MRI showed
an ischemic lesion in the left thalamus (Fig. 1e). Inflamma-
tory markers as well as cytokines IL-6 and s-IL2R were
increased and ANA were positive (1:1280) with a
homogenous pattern; anti-ENA-, anti-ds DNA-antibodies,
anticardiolipin (aCL)- and anti-beta2-glycoprotein (anti-
ß2GP)-antibodies as well as ANCA were negative, and cir-
culating immune complexes were unremarkable, as were
levels of C3, C4 and CH50. Suspecting a systemic auto-
immune disease with neuroinflammation, therapy with
oral steroids at a dose of 2 mg/kg and low-dose ASA was
started with complete recovery of neurologic symptoms
within several days. Four weeks later, while tapering
steroids, the patient developed a left-sided facial palsy. A
repeated MRI revealed an ischemic lesion in the right
thalamus; CRP and ESR were markedly elevated. Steroids
were increased to 2 mg/kg and neurological symptoms
again resolved within a few days. Steroids thereafter were
tapered off over 3 weeks. Two months later, the patient
complained of recurrent abdominal pain, and mouth
Fig. 1 Clinical findings of the patients. a Livedo reticularis of patient 1. b, c, d Erythematous skin lesions of patient 2, which appear as discoid
plaques or annular papules. e T2-weighted magnetic resonance image of the brain of patient 2 showing a recent ischemic lesion in the right
thalamus and an older lesion in the left thalamus. f Blue finger syndrome due to vascular occlusion in patient 2
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ulcers accompanied by relapsing fever and fatigue. Ultra-
sound examination of abdomen and urinary tract, echo-
cardiography and chest-x-rays were without pathologic
findings, as were liver and renal function tests. Despite
elevated calprotectin in stool (480 μg/g), endoscopy of the
gastrointestinal tract was unremarkable. Thereafter, he
presented with annular lesions on the face and sun-
induced eczematous lesions on both hands (Fig. 1c-d). At
age 3.5 years, Raynaud’s phenomenon, pain and morning
stiffness affecting several large and small joints were noted
along with livedo racemosa. At follow-up visits, he pre-
sented with arthritis of the left metacarpophalangeal
(MCP) joints. An ultrasound revealed nonerosive syno-
vitis. He continued to show chronic inflammation, hyper-
gammaglobulinemia and an ANA titer of 1:2560. Arthritis
of MCP joints persisted and he developed a blue finger
syndrome of the third digit (Fig. 1f). Pulse oscillography
revealed a critically limited perfusion due to occlusion of
small digital arteries. Therapy with nifedipine, oral steroids
and azathioprine (AZA) was initiated and low-dose ASA
continued. Under this regimen, arthritis, abdominal pain
as well as febrile episodes significantly improved. After
3 years of treatment, AZA was stopped. Continuing low-
dose ASA, the patient showed mildly impaired fine motor
skills and marked livedo accompanied by slightly in-
creased markers of inflammation as well as an ANA titer
of 1:1280.
Since early-onset inflammatory systemic vascular dis-
ease affecting the brain and skin is commonly observed
in patients with type I interferonopathies, both patients
were investigated for signs of an interferon signature in
blood [8]. Quantitative RT-PCR of peripheral blood cells
revealed enhanced expression of interferon-stimulated
genes demonstrating constitutive type I IFN activation
(Fig. 2c-d). Based on these clinical findings, the patients
were initially suspected of Aicardi-Goutières syndrome
(AGS). However, no mutation in any of the seven known
AGS genes were detected.
Whole exome sequencing of patient 1 was therefore
performed to identify the disease-causing mutation.
Variant analysis and filtering assuming a recessive mode
of inheritance revealed two missense mutations within
Fig. 2 Genetic and molecular findings. a Pedigree of the family with ADA2 deficiency. Solid symbols indicate affected persons, open symbols unaffected
relatives, squares male persons, circles female persons. The amino acid changes are indicated next to the symbols. b The upper panel shows
electropherograms with the two heterozygous CECR1 mutations, c.139G>C (p.Gly47Arg) and c.1223G>A (p-Cys408Tyr), identified in both siblings. The
lower panels show alignments of ADA2 protein sequences from different species. The positions of the altered amino acid residues Gly47 and Cys408 are
marked by arrows. Highly conserved regions are marked in red and less conserved regions are indicated in blue. c, d Expression of interferon-stimulated
genes, IFI27, IFI44, IFI44L, IFIT1, ISG15, RSAD2 and SIGLEC1 in peripheral blood. Shown is the fold-change of the respective mRNA relative to the mean
expression of 10 healthy controls
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the CECR1 gene, c.139G>C (p.Gly47Arg) located in
exon 1 and c.1223G>A (p.Cys408Tyr) in exon 7 (Fig.
2a, b). Targeted Sanger sequencing confirmed the
presence of both mutations in patient 2, the affected
brother. Furthermore, both parents were found to
carry only one of the two mutations, in line with
compound heterozygosity for both mutations in the
affected sons (Fig. 2a-b). While the first mutation
(p.Gly47Arg) has been described as the most common
pathogenic variant in ADA2-deficiency [1, 2], the sec-
ond mutation (p.Cys408Tyr) has previously not been
associated with a disease phenotype. This variant is
listed in the ENSEMBL database as variant
rs751280698 and was found only once in a single in-
dividual in the heterozygous state within the ExAc
data base corresponding to an allele frequency of 8.23
× 10−6, which is compatible with a rare disease-
causing recessive variant. p.Cys408Tyr causes the
exchange of a cysteine residue to tyrosine within the
adenosine/adenosine monophosphate deaminase
domain and is predicted to be “probably damaging”
by PolyPhen (score 0.998) and “deleterious” by SIFT
(score 0). Alignment of the ADA2 protein sequences
by hierarchical clustering revealed a high degree of
conservation of amino acid residue Cys408 of the
ADA2 protein across multiple species including
zebrafish (Fig. 2b).
To further explore the functional consequences of the
CECR1 mutations, ADA2 enzyme was measured in
patients and parents as well as in healthy controls by the
dried plasma spot method as previously described [1]. A
marked reduction in enzyme activity was noted in both
patients (patient 1, 0.6 mU/g; patient 2, 0.04 mU/g)
compared to healthy controls (control 1, 81.3 mU/g;
control 2, 120.0 mU/g). The level of enzyme activity was
below the average enzyme activity of 29 ADA2-deficient
patients of 4.7 ± 4.2 mU/g (range, 0.6–17.2 mU/g),
confirming that both, p.Gly47Arg and p.Cyc408Tyr act
as loss-of-function mutations.
After ADA2 deficiency was diagnosed, ASA was
stopped in both patients and treatment with anti-TNF
agent was recommended.
Discussion
In this report, we describe two siblings with early-onset
recurrent strokes, systemic inflammation, erythematous
skin lesions, livedo reticularis as well as arthritis accom-
panied by high ANA titers and ascribe this inflammatory
phenotype to biallelic CECR1 mutations. While one of
the identified mutation p.Gly47Arg represents the most
common mutation found in patients with PAN, the sec-
ond mutation p.Cys408Tyr is novel and affects a highly
conserved residue within the catalytic domain of the
ADA2 enzyme. Functional testing confirmed a marked
reduction of ADA2 enzyme activity in agreement with a
loss of function. Whereas clinical features of vasculitis
and mild immunodeficiency due to cytopenia and hypo-
gammaglobulinemia are commonly observed in patients
with ADA2 deficiency, autoimmunity has only rarely
been described [1, 4–7].Thus, low ANA titers have been
reported in 9 out of 45 ADA2-deficient patients [3],
while hypergammaglobulinemia has been reported only
in two siblings with additional IL-17RA deficiency [9].
An autoimmune phenotype with discoid skin lesions
with partial photosensitivity, oral ulcerations, non-
erosive arthritis, abdominal pain as well as neurological
signs due to cerebrovascular disease, together with the
constantly high ANA titers, transiently elevated lupus
anticoagulants, anti-nucleosome antibodies, hypergam-
maglobulinemia and anemia, has not been described
previously. These findings are overlapping with features
seen in patients with systemic lupus erythematosus
(SLE) and other type I interferon-driven disorders [10].
Interestingly, both patients exhibited a repeatedly high
expression of interferon-stimulated genes in blood indi-
cating constitutive type I interferon activation. Such an
interferon signature is typically seen in patients with SLE
or Mendelian forms of type I interferon-driven disorders
such as chilblain lupus or Aicardi-Goutières syndrome
[11, 12]. As upregulation of IFN stimulated genes has
recently been observed in 4 patients with ADA2
deficiency, our data suggest a contributing pathogenetic
role of systemic type I interferon activation in ADA2
deficiency [13, 14]. Further studies are necessary to
evaluate the potential efficacy of JAK inhibition, besides
the proven therapeutic effect of TNF inhibitors, for this
entity.
Conclusion
Our findings demonstrate that ADA2 deficiency can cause
an autoimmune phenotype, extending the phenotypic
spectrum PAN. This implies that ADA2 deficiency should
be considered in the differential diagnosis of pediatric pa-
tients presenting with early-onset autoimmune phenom-
ena as this knowledge will be important for clinical
decisions with respect to specific treatment options. Con-
stitutive type I interferon activation in patient blood sug-
gests a possible role of type I interferon in disease
pathogenesis, although the underlying molecular mecha-
nisms remain to be investigated.
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